Nasdaq:US$18.41 (+0.16) | HKEX:HK$30.35 (+1.05) | AIM:£3.03 (+0.07)
搜索结果
上一篇文章   |   下一篇文章
公告及新闻稿, 肿瘤学 / 免疫学 | 2009-11-05

Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans